Exploration of Icotinib Combined with Chemotherapy and Bevacizumab in Perioperative Treatment of Stage Ⅱb-Ⅲb EGFR-sensitive Mutant Non-small Cell Lung Cancer (NSCLC)

Start Date31 Aug 2025

Sponsor / Collaborator-

NCT06955325

/ Not yet recruitingPhase 3IIT

A Randomized, Phase III Umbrella Trial of Adjuvant Therapy Versus Observation in Completely Resected High-Risk Stage IA-IB Non-Small Cell Lung Cancer Based on Oncogenic Driver Mutations

This study explores how adjuvant therapy affects survival in completely resected high-risk stage IA-IB NSCLC patients with different driver gene mutations.

Start Date01 May 2025

Sponsor / Collaborator

The First Affiliated Hospital of Guangzhou Medical University

ChiCTR2400094179

/ RecruitingNot ApplicableIIT

An observational study on drug holidays during three years of adjuvant therapy with icotinib in patients with IA1-IB stage lung cancer with high-risk factors and positive minimal residual disease (MRD)

Start Date18 Dec 2024

Sponsor / Collaborator-

100 Clinical Results associated with Icotinib Hydrochloride

100 Translational Medicine associated with Icotinib Hydrochloride

100 Patents (Medical) associated with Icotinib Hydrochloride

577

Literatures (Medical) associated with Icotinib Hydrochloride

01 Nov 2025·ACTA PHARMACOLOGICA SINICA

Modeling exposure-driven adverse events of EGFR TKIs in the treatment of patients with non-small cell lung cancer

Article

Author: Liu, Wei ; Yong, Ling ; Luo, Ping-Yao ; Cao, Bao-Shan ; Liu, Yan'e ; Gan, En-Ze ; Cai, Lei ; Jian, Wei-Zhe ; Liu, Chen ; Zhou, Tian-Yan ; Bao, Tian-Yu ; Wang, Tian-Yu

The adverse events associated with antitumour drugs have recently emerged as an increasingly significant clinical concern. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) serve as pivotal therapeutic agents for non-small cell lung cancer (NSCLC). However, considerable interindividual variability exists in drug exposure, along with a high incidence and severity of adverse events. In this study, we quantitatively investigated the impacts of EGFR TKI exposure and other covariates on the severity of the maximum grade of drug-related adverse events (MDRAE) in NSCLC patients treated with EGFR TKIs. Data were collected from 277 patients treated with gefitinib, icotinib, afatinib or osimertinib. Population pharmacokinetic (PopPK) models were constructed for each drug, and individual exposure metrics were derived through model simulations. Normalized individual exposures to different EGFR TKIs based on their IC₅₀ values and MDRAE data were integrated to develop an ordinal logistic regression model for an exposure-safety analysis. A user-friendly nomogram was subsequently designed. The probability of high-grade MDRAE was significantly associated with normalized exposure levels, a history of EGFR TKI treatment, sex and other factors. Model simulations revealed substantial interindividual variability in drug exposure and the probability of different grades of MDRAE for the same treatment regimen. This study quantitatively elucidates the influences of drug exposure and other critical factors on safety, thereby contributing to the formulation of individualized treatment strategies to prevent and promptly address drug safety-related issues.

01 Aug 2025·LUNG CANCER

Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER)

Article

Author: Yang, Xin ; Wang, Yuzhao ; Zhuo, Minglei ; Chen, Jinfeng ; Yan, Shi ; Wang, Jia ; Wu, Nan ; Lv, Chao ; Lu, Fangliang ; Xiong, Hongchao ; Zhang, Shanyuan

BACKGROUND:

EGFR tyrosine kinase inhibitors (EGFR-TKIs) have shown activity in the neoadjuvant setting of EGFR-mutant (EGFRm) non-small cell lung cancer; however, data on the combination of neoadjuvant EGFR-TKIs plus chemotherapy are limited. This study aimed to evaluate the safety and efficacy of neoadjuvant icotinib plus chemotherapy for stage II-IIIB EGFRm lung adenocarcinoma.

METHODS:

NEOIPOWER is a single-arm, phase II study (NCT05104788). Eligible adult patients with resectable, stage II-IIIB, EGFRm lung adenocarcinoma received 8 weeks of 125 mg icotinib three times daily plus two 21-day cycles of chemotherapy (pemetrexed 500 mg/m² and carboplatin AUC5 on day 1), followed by surgical resection. The primary endpoint was major pathologic response (MPR) rate. Secondary endpoints were R0 resection rate, objective response rate (ORR), pathologic complete response (pCR), disease control rate (DCR), disease-free survival (DFS), overall survival, and safety.

RESULTS:

From October 25, 2021, to April 2, 2023, 30 patients were enrolled and completed neoadjuvant therapy. MPR was observed in 6.7 % of patients (95% CI, 0.8-22.1%), which did not meet the primary endpoint. No patients had pCR. Twenty-eight (93.3 %) patients underwent surgery, of whom 27 (96.4 %) achieved R0 resection, and pathological downstaging was observed in 10 (35.7 %) patients. The ORR was 83.3 % (95% CI, 65.3-94.4 %) and DCR was 96.7 % (95% CI, 82.8-99.9 %) among 30 treated patients. With a median follow-up of 25.0 (range, 6.4-33.6) months, the median DFS was not reached (95% CI, 25.1-not estimable), and the 2-year DFS rate was 92.0 %. Grade 3 treatment-related adverse events (TRAEs) were reported in 6 (20.0 %) patients and mainly included leukopenia (6.7 %) and neutropenia (6.7 %). No grade 4 or 5 TRAEs were observed, and no deaths occurred.

CONCLUSION:

Neoadjuvant icotinib combined with chemotherapy did not meet its primary endpoint for MPR rate in resectable stage II-IIIB EGFRm lung adenocarcinoma, but demonstrated a manageable safety profile.

03 Jul 2025·JOURNAL OF DRUG TARGETING

Epidermal growth factor receptors unveiled: a comprehensive survey on mutations, clinical insights of global inhibitors, and emergence of heterocyclic derivatives as EGFR inhibitors

Review

Author: Pasha, Ismail ; H P, Gagana ; Shivanandappa, Thippeswamy Boreddy ; B L, Kavya ; K N, Purushotham ; K M, Gagana ; Hussain, Shalam M. ; Ahmed, Mohammed Muqtader ; Pasha, T. Y. ; C, Manojmouli ; Rahamathulla, Mohamed

Mutations that overexpress the epidermal growth factor receptor (EGFR) are linked to cancers like breast (15-20%), head and neck (10-15%), colorectal (5-8%), and non-small cell lung cancer (10-50%), especially in East Asian populations. EGFR activation stimulates 'RAS/RAF/MEK/ERK, PI3K/Akt, and MAPK' pathways, which enhance cell division, survival, angiogenesis, and tumour growth while inhibiting apoptosis and metastasis. Secondary mutations (e.g. 'T790M', 'C797S'), off-target effects, and resistance due to alternate pathway activation reduce the efficacy of currently available EGFR inhibitors. To address these issues, 'novel heterocyclic inhibitors with structural versatility were developed to improve selectivity and binding affinity for mutant EGFR forms'. These new EGFR reduce side effects, enhance pharmacokinetics, and enhance therapeutic efficacy at low concentrations. This review focuses on 'EGFR mutations in various cancers' detailing the biochemical effects, clinical profiles, and binding interactions of globally approved EGFR inhibitors. Furthermore, it focuses into recent progress in nano-formulations and the development of heterocyclic derivatives that can successfully 'target mutant EGFRs' through varied synthesis methods. These inhibitors have the potential to have better binding affinities, selectivity's, and less side-effect. Further research required to refine the structures and develop nanoformulations of EGFR-targeted therapeutics in order to improve therapeutic efficiency and, provide more effective cancer treatments.

News (Medical) associated with Icotinib Hydrochloride

19 Dec 2024

·www.fiercepharma.com

Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer

Before the FDA go-ahead, ensartinib was first approved in China in 2020. Following in the footsteps of several Big Pharma companies, another ALK inhibitor has made its entry into the U.S. The new entrant is ensartinib from Xcovery Holdings, a subsidiary of China’s Betta Pharmaceuticals. The FDA on Wednesday approved the drug under the brand name Ensacove as a first-line treatment for ALK-positive non-small cell lung cancer among patients who’ve not previously received an ALK inhibitor.Before the FDA go-ahead, ensartinib was first approved in China in 2020 under the trade name Beimeina. There, the drug moved into the first-line setting in 2022.Betta noted that Ensacove marks the first innovative targeted lung cancer drug developed by a Chinese company to make it to the global market. Still, the drug is entering a niche market dominated by Big Pharma companies.As a second-generation ALK inhibitor, Ensacove is clearly better than Pfizer’s first-generation Xalkori. But Roche’s Alecensa, Takeda’s Alunbrig and Pfizer’s third-generation med Lorbrena have all outperformed Xalkori to secure their respective first-line approvals from the FDA. Novartis also has an ALK inhibitor, Zykadia, which was cleared for first-line treatment in 2017 based on a comparison with chemotherapy.The FDA’s nod for Ensacove came more than three years after results from the drug’s first-line eXalt3 study were published in JAMA Oncology. Compared with Xalkori, Ensacove reduced the risk of progression or death by 44% in first-line ALK-positive NSCLC, according to the FDA. No statistically significant difference in overall survival was observed, as Ensacove was linked to a non-statistically significant 12% lower risk of death.The data cited by the FDA, which will be featured on Ensacove’s U.S. label, appear to come from a longer follow-up of eXalt3. Ensacove’s efficacy data were not very differentiated compared with those Big Pharma offerings that have been available on the U.S. market for years.The current ALK leader, Roche’s Alecensa, broke into the first-line ALK setting seven years ago after the phase 3 ALEX trial showed it slashed the risk of disease worsening or death by 47% versus Xalkori. The number later expanded to 57% at the trial’s final progression-free survival analysis. By that time, overall survival data were also immature but showed a 33% improvement trend in favor of the Roche med.What’s more, Alecensa in April jumped into early-stage disease with a first-in-class FDA nod to treat ALK-positive NSCLC as an adjuvant treatment following tumor resection.Ensacove has its own ongoing phase 3 in the adjuvant setting, albeit only among Chinese patients. It’s estimated that about 5% of NSCLC cases are ALK-positive, and treatment can last for a long time for many patients. In the first nine months of 2024, Alecensa brought in 1.15 billion Swiss francs ($1.28 billion) in sales, while Pfizer’s Lorbrena commanded $538 million and Takeda’s Alunbrig generated 25.6 billion Japanese yen ($163 million). Still, those are large numbers compared with Betta’s 2.34 billion Chinese yuan ($321 million) of total revenue earned during the same period from five products, including ensartinib in China.Betta Pharma is revered as a pioneer in China’s biotech industry. The company’s EGFR tyrosine kinase inhibitor icotinib, a competitor to AstraZeneca’s Tagrisso, was the first targeted cancer drug invented and fully owned by a Chinese company. Its approval by Chinese authorities in 2011 was hailed as a landmark event.But the company has fallen behind many of its peers because of its heavy reliance on traditional small-molecule drugs rather than newer technologies.

Drug ApprovalPhase 3Clinical ResultBiosimilar

29 Nov 2024

·www.echemi.com

Pfizer Partners with China Resources for Operations of Four Oncology Drugs in China!

On November 26, 2024, Pfizer announced a strategic cooperation with China Resources Pharmaceutical Commercial to manage the commercialization of four oncology treatments in China. These medications include Anastrozole, Abiraterone, Palbociclib, and Crizotinib, which will be managed by China Resources. Pfizer’s China President, Peng Zhenke, and China Resources’ Deputy General Manager, Han Yuewei, attended the signing ceremony. Among these drugs, Icotinib and Epirubicin have already been included in the alliance procurement list, while Palbociclib and Crizotinib are subject to national negotiations, resulting in significant price reductions. Palbociclib also appeared in the newly published tenth national procurement list, indicating further price cuts. The collaboration will commence on December 1, with Pfizer working closely with China Resources to ensure a smooth transition for affected employees.

30 May 2023

·www.globenewswire.com

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

C4 Therapeutics to Receive a $10 Million Upfront Payment, a $25 Million Equity Investment and is Eligible to Receive up to $357 Million for Development and Commercial Milestones Plus Royalties on Net Sales in Greater China Betta Pharmaceuticals to Develop and Commercialize CFT8919 in Greater China and Eligible to Receive Royalties on Net Sales Outside of Greater China The Exclusive Licensing Agreement with Betta Pharmaceuticals Accelerates Development of CFT8919 in Key International Markets WATERTOWN, Mass. and HANGZHOU, China, May 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, and Betta Pharmaceuticals Co. Ltd (Betta) (SZ300558), a leading pharmaceutical company focusing on the development of innovative oncology therapies in China, today announced an exclusive licensing agreement for the development and commercialization of CFT8919 in Greater China (including Hong Kong SAR, Macau SAR and Taiwan). CFT8919 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer (NSCLC) patients. Under the terms of the agreement, C4T expects to receive $35 million, which includes $10 million in upfront cash as well as a $25 million one-time equity investment, to be completed following the receipt of required regulatory approvals and other customary closing conditions. Additionally, C4T is eligible for up to $357 million in potential milestones and low to mid-double-digit percent royalties on net sales in the licensed territories. Betta will be responsible for the development, manufacturing and commercialization of CFT8919 in the licensed territories and is eligible to receive low single-digit percent royalties on net sales outside of Greater China. C4T retains the right to develop and commercialize CFT8919 in all territories outside of Greater China. “We are excited to partner with Betta to develop CFT8919, an orally bioavailable allosteric EGFR L858R degrader, with the potential to treat NSCLC patients with EGFR L858R mutations in Greater China and beyond,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “With their strong track record of developing and commercializing NSCLC therapies in China, we believe Betta is the ideal partner to advance CFT8919 clinical development in a region where there is a high prevalence of lung cancer patients with the EGFR L858R mutation.” “The collaboration with C4T is another important collaboration for Betta’s partnerships with top-tier biotech companies,” said Lieming Ding, chairman and chief executive officer of Betta. “The collaboration will further expand Betta’s product pipeline and improve the productivity of the company's R&D, from discovery to clinical development, and to commercialization. We will leverage the capabilities and resources of both parties and continue developing innovative drugs to benefit more patients.” In preclinical studies, CFT8919 is active in in vitro and in vivo models of EGFR L858R driven NSCLC with broad coverage of on-target resistant mutations and intracranial activity, with the potential to prevent or treat brain metastases in these patients. CFT8919 has been designed to bind to an allosteric site, which is uniquely created by the L858R activating mutation, allowing for exquisite selectivity for this mutation. Further, CFT8919 was designed to be effective independent of secondary EGFR mutations, for example T790M and/or C797S. Additionally, CFT8919 demonstrated potent anti-proliferation activity against a panel of cell lines harboring either L858R single mutation or L858R with additional EGFR mutations that confer resistance to approved EGFR inhibitors such as osimertinib or erlotinib, while sparing cell lines with wild-type EGFR. In China, approximately 693,000 patients were diagnosed with NSCLC in 2020 and approximately 40% of these cases are driven by the EGFR mutation. The L858R mutation is the second most common EGFR mutation, found in approximately 40% of NSCLC patients with EGFR mutations in China. Typically, these patients experience a less durable response to approved EGFR inhibitors, including osimertinib. C4T is on track to submit an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for CFT8919 for the treatment of NSCLC in the first half of 2023. MSQ Ventures served as an advisor to C4T and Goodwin Procter LLP served as legal counsel to C4T. Han Kun Law Offices served as legal counsel to Betta. About CFT8919CFT8919 is an orally bioavailable allosteric BiDAC™ degrader that is designed to be potent and selective against EGFR bearing an oncogenic L858R mutation. In preclinical studies, CFT8919 is active in in vitro and in vivo models of L858R driven non-small cell lung cancer. Importantly, CFT8919 retains full activity against additional EGFR mutations that confer resistance against approved EGFR inhibitors including L858R-C797S, L858R-T790M, and L858R-T790M-C797S. About C4 TherapeuticsC4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit www.c4therapeutics.com. About Betta PharmaceuticalsBetta Pharmaceuticals Co., Ltd. (SZ300558) is a commercial-staged pharmaceutical company dedicated to the development of innovative oncology products to meet high unmet medical needs. With about 2,000 employees in Hangzhou and Beijing, Betta's integrated R&D platform ranges from small-molecule to biologics discovery, clinical development, manufacturing, sales and marketing. Betta's leading product – icotinib (Conmana®), the first innovative oncology product domestically developed and launched in China – is one of the top selling targeted therapies for patients with non-small cell lung cancer, having achieved more than 13 billion RMB accumulated sales since launched and benefited more than 500,000 patients in China. Betta currently has 3 marketed products, 15 programs in clinical development and 2 molecules under NDA review by the NMPA. Throughout the years, Betta has set up strategic partnerships with Xcovery LLC., Merus N.V., Agenus Inc. and other top-tier biotech companies, with the ultimate objective to deliver innovative health solutions around the world. For more information, please visit http://www.bettapharma.com/en.php. Forward-Looking StatementsThis press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO® platform in the development of novel, selective, orally bioavailable BiDAC™ and MonoDAC™ degraders; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for and receipt of regulatory authorization related to clinical trials and other clinical development activities including clinical trial commencement; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; regulatory developments in the United States and foreign countries; our ability to fund our future operations; our ability to realize development and commercialization milestones and receive royalties on the commercial sale of our product candidates; our ability to realize the anticipated benefits of this collaboration; and our ability to complete the contemplated sale of equity securities. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that the results of preclinical studies and/or clinical trials will or will not be predictive of results in connection with future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law. C4T Contacts:Investors: Courtney SolbergSenior Manager, Investor RelationsCSolberg@c4therapeutics.com Media: Loraine Spreen Director, Corporate Communications & Patient Advocacy LSpreen@c4therapeutics.com Betta Pharmaceuticals Contact:Jianhao Shen Director, Securities AffairsJianhao.shen@bettapharma.com

License out/in

100 Deals associated with Icotinib Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Icotinib Hydrochloride	L01XE48	DB11737

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	China	Betta Pharmaceuticals Co., Ltd.	07 Jun 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lung Cancer with Brain Metastasis	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	20 Jul 2018
EGFR-mutated non-small Cell Lung Cancer	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	02 Jun 2015
Adenocarcinoma of Lung	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	01 Sep 2014
EGFR Mutation Lung Cancer	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	01 Sep 2014
EGFR positive non-small cell lung cancer	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	01 Sep 2014
Advanced Lung Adenocarcinoma	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	01 Dec 2012
EGFR positive Adenocarcinoma of Lung	Phase 3	China	Betta Pharmaceuticals Co., Ltd.	01 Dec 2012
Brain metastases	Phase 2	-	Betta Pharmaceuticals Co., Ltd.	01 Dec 2018
Non-small cell lung cancer stage IIIB	Phase 2	China	Betta Pharmaceuticals Co., Ltd.	09 May 2018
progressive non-small cell lung cancer	Phase 2	China	Betta Pharmaceuticals Co., Ltd.	01 Jan 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01996098 (ICTAN \| GASTO1002, Signal Transduct Target Ther \| NEWS 1 \| NEWS 2) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer Adjuvant EGFR Mutation	251	Icotinib 125 mg, three times daily for 12 months	vmnmtdwqog(hibesmaoug) = ushrobuzao sqgnmxblqt (ozhixmcuvb ) View more	Positive	28 Aug 2025
				Icotinib 125 mg, three times daily for 6 months	vmnmtdwqog(hibesmaoug) = resbcunhnc sqgnmxblqt (ozhixmcuvb ) View more
NCT02264210 (CORIN (GASTO1003), ASCO2025)	Phase 2	EGFR-mutated non-small Cell Lung Cancer Adjuvant EGFR-mutated	128	Icotinib (125mg, three times daily, 12 months)	wtvtzbkauo(fnrcliciub) = wnlauzdlpr yysngyvkto (qvkyhhzdvx ) View more	Positive	30 May 2025
				icotinib (Observation)	wtvtzbkauo(fnrcliciub) = rbztvbarsb yysngyvkto (qvkyhhzdvx ) View more
NEWS Manual	Phase 3	EGFR positive non-small cell lung cancer EGFR L858R \| EGFR Exon 19 Deletion	118	埃克替尼单药组	wfzhdcrixl(xgpiaunfvd) = jvgtqafrqm gjrkcceyne (ttrgzishzl ) View more	Positive	14 Oct 2024
				埃克替尼联合TRT组	wfzhdcrixl(xgpiaunfvd) = zwbhcplarf gjrkcceyne (ttrgzishzl ) View more
EVIDENCE (WCLC2024)	Phase 3	EGFR positive non-small cell lung cancer Adjuvant ctDNA-based molecular residual disease (MRD)	179	Icotinib	ujkukvcdaj(lkdzhdmxtd): HR = 0.4 (95% CI, 0.2 - 0.6)	Positive	10 Sep 2024
				Chemotherapy
ChiCTR1800016948 \| NCT05104788 (NEOIPOWER, WCLC2024) Manual	Phase 2	EGFR positive Adenocarcinoma of Lung Neoadjuvant EGFR Mutation	133	Chemotherapy	hyvnwuesbo(crifurkxbp) = galvlwfigx qmppojsyir (eqowwnyhbj )	Positive	09 Sep 2024
				First-generation EGFR-TKIs	hyvnwuesbo(crifurkxbp) = zgbgednuwl qmppojsyir (eqowwnyhbj )
NCT01996098 (ICTAN, GASTO1002, ASCO2024) Manual	Phase 3	EGFR-mutated non-small Cell Lung Cancer Adjuvant EGFR Mutation	251	Icotinib 12 months	kjowtuzarq(ydmarlfssj) = gwsrhskuhn gddvfejwzk (svfuuuoqmj, 43.3 - 80.3) View more	Positive	24 May 2024
				Icotinib 6 months	kjowtuzarq(ydmarlfssj) = ofopfwehvb gddvfejwzk (svfuuuoqmj, 44.8 - 81.6) View more
WCLC2023 Manual	Phase 1/2	EGFR-mutated non-small Cell Lung Cancer First line EGFR Mutation	24	Aumolertinib+Icotinib	awviggoefm(akrrkwadmg) = aumolertinib 110 mg po qd plus icotinib 125mg po tid nvyqqilzoz (rtfjkmpehh ) View more	Positive	11 Sep 2023
NCT01929200 (ICOMPARE study, Pubmed)	Phase 2	EGFR positive Adenocarcinoma of Lung Adjuvant	109	1-year icotinib	ewkifufijp(saurrxbrtw) = ozoeatddss qrwrxtlvvt (dhzxmcopln, 26.6 - 44.8)	Positive	20 Jun 2023
				2-year icotinib	ewkifufijp(saurrxbrtw) = edeqiuzncm qrwrxtlvvt (dhzxmcopln, 33.1 - 70.1)
NCT02264210 (GASTO1003, CORIN, Pubmed)	Phase 2	EGFR-mutated non-small Cell Lung Cancer Adjuvant	128	Adjuvant icotinib	vabrvncsyf(nhnsajjmvz) = iksualzchn tcqvkkswgh (zshulrvaby, 91.3 - 99.9)	Positive	01 Mar 2023
				icotinib (Observation)	vabrvncsyf(nhnsajjmvz) = hjxdmfxmds tcqvkkswgh (zshulrvaby, 75.1 - 92.9)
ESMO_ASIA2022	Not Applicable	Advanced Lung Adenocarcinoma First line	105	icotinib	dtgwroyytk(bcudqohmhe) = umqffufonf kmdmomwxcx (hkcovrgeta )	-	03 Dec 2022
				icotinib plus vinorelbine	dtgwroyytk(bcudqohmhe) = kosdezvixv kmdmomwxcx (hkcovrgeta )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Icotinib Hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation